Back to search

Peptide record

TPDB02799

PTP5 PTP6 Antibacterial Anticancer Toxicity standard

13 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB02799

Peptide_Name

PTP5 PTP6

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.

Sequence

FLKLLKKLAAKLF

FASTA

>TPDB02799|Antibacterial;Anticancer;Toxicity|length=13
FLKLLKKLAAKLF

Formula C78H133N17O14

Absent Amino Acids RNDCEQGHIMPSTWYV

Common Amino Acids L

Mass 1533.02

PI 11.00

Basic Residues 4

Acidic Residues 0

Hydrophobic Residues 9

Net Charge +4

Boman Index -1.44

Hydrophobicity 0.969

Aliphatic Index 165.38

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

Amino Acid Distribution

A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 4 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

Formula

C78H133N17O14

Mass

1533.02

11.00

Net Charge

Boman Index

-1.44

Hydrophobicity

0.969

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antibacterial

Origin

Gaegurin

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=9.09 µg/ml

Detail Source Activity Anticancer

Activity Measurement 9.09 µg/mL

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13.94 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13.94 µg/mL

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=15.11 µg/ml

Detail Source Activity Anticancer

Activity Measurement 15.11 µg/mL

Target

Cancer Type Renal Cancer

Cell Line 293

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=14 µg/ml

Detail Source Activity Anticancer

Activity Measurement 14 µg/mL

Target

Cancer Type Renal Cancer

Cell Line 293

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 5 Activity

Activity

Activity Raw

Not Available

Detail Source Activity Anticancer

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13.27 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13.27 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 7 Activity

Activity

Activity Raw

Not Available

Detail Source Activity Anticancer

Target

Cancer Type Liver Cancer

Cell Line Hep3B

Tissue Affected Liver

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=15.07 µg/ml

Detail Source Activity Anticancer

Activity Measurement 15.07 µg/mL

Target

Cancer Type Liver Cancer

Cell Line Hep3B

Tissue Affected Liver

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=5.43 µg/ml

Detail Source Activity Anticancer

Activity Measurement 5.43 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=17.56 µg/ml

Detail Source Activity Anticancer

Activity Measurement 17.56 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 96-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2003

Evidence 11 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 14.00±1.46 µg/mL

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 14.00±1.46 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Target Cell Human embryonic kidney HEK293T cells

Source & Reference

Database Source NA

Source Database DBAASP

Reference

In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. | Peptides | 2003